Your browser doesn't support javascript.
loading
Glucagon-like Peptide 1 Receptor Agonist use and the effect on diabetic retinopathy: An uncertain relationship.
Hui, Benjamin T K; Yeong, Jian Lee; Peto, Tunde; Willoughby, Colin E.
Afiliación
  • Hui BTK; Department of Ophthalmology, Royal Victoria Hospital, Belfast, Northern Ireland, UK.
  • Yeong JL; Department of Ophthalmology, Royal Victoria Hospital, Belfast, Northern Ireland, UK.
  • Peto T; Department of Ophthalmology, Royal Victoria Hospital, Belfast, Northern Ireland, UK; Institute of Clinical Science, Queens University, Belfast, Northern Ireland, UK.
  • Willoughby CE; Department of Ophthalmology, Royal Victoria Hospital, Belfast, Northern Ireland, UK; Genomic Medicine, Biomedical Sciences Research Institute, Ulster University, Coleraine, Northern Ireland, UK. Electronic address: c.willoughy@ulster.ac.uk.
Peptides ; 178: 171240, 2024 Aug.
Article en En | MEDLINE | ID: mdl-38705472
ABSTRACT
Glucagon-like Peptide 1 Receptor Agonists (GLP-1 RAs) are a group of relatively novel medications for the treatment of diabetes mellitus. These medications can mimic the naturally occurring incretins of the body, which promote the release of insulin in response to hyperglycaemia. The anti-glycaemic effects of these medications can be profound and carry other metabolic benefits such as promoting weight loss. Clinical trials have shown GLP-1 RAs are safe to use from a cardiovascular perspective. However, some trials have suggested a link between GLP-1 RA use and worsening diabetic retinopathy. The conclusions surrounding this link are poorly established as data is drawn primarily from cardiovascular outcome trials. If an association does exist, a possible explanation might be the observed phenomenon of early worsening diabetic retinopathy with rapid correction of hyperglycaemic states. Trials which look at diabetic retinopathy as a primary outcome in relation to use of GLP-1 RAs are sparse and warrant investigation given the growing use of this group of medications. Therefore currently, it is uncertain what effect, beneficial or adverse, GLP-1 RA use has on diabetic retinopathy. This article provides an overview of GLP-1 RA use as a treatment for diabetes mellitus and the current understanding of their relationship with diabetic retinopathy.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Retinopatía Diabética / Receptor del Péptido 1 Similar al Glucagón / Hipoglucemiantes Límite: Humans Idioma: En Revista: Peptides Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Retinopatía Diabética / Receptor del Péptido 1 Similar al Glucagón / Hipoglucemiantes Límite: Humans Idioma: En Revista: Peptides Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos